US Physical Therapy Inc

USPH is in a Stage 2 advancing phase within a confirmed uptrend, marked by higher highs and higher lows above rising EMAs. Price is extended above the 9/20 EMA regime and approaching the 200 DMA with extreme overbought readings, suggesting an imminent pullback. We will stalk for a corrective retracement into the 9/20 EMA and 50 DMA support zones before scaling exposure, consistent with a momentum‐oriented execution style.

• ↑Analysts forecast 22–25% upside to $88–$102 target prices
• ↑7.9% YoY revenue growth driven by outpatient rehabilitation demand
• ↓P/S ratio of 1.5x exceeds industry average of 1.4x